Needham & Company LLC reiterated their buy rating on shares of Heron Therapeutics (NASDAQ:HRTX – Free Report) in a report issued on Wednesday, Benzinga reports. They currently have a $5.00 price target on the biotechnology company’s stock. Separately, Rodman & Renshaw initiated coverage on shares of Heron Therapeutics in a research note on Thursday, June […]

Foghorn Therapeutics (NASDAQ:FHTX – Free Report) had its target price hoisted by Morgan Stanley from $6.00 to $9.00 in a report published on Tuesday morning, Benzinga reports. The firm currently has an equal weight rating on the stock. Several other research analysts have also recently issued reports on the stock. Evercore ISI began coverage on […]

Canaccord Genuity Group initiated coverage on shares of Core Scientific (NASDAQ:CORZ – Free Report) in a research report sent to investors on Monday, Marketbeat reports. The brokerage issued a buy rating and a $16.00 price objective on the stock. A number of other equities analysts have also recently issued reports on the stock. LADENBURG THALM/SH […]

StockNews.com cut shares of Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) from a strong-buy rating to a buy rating in a research report report published on Monday. TEVA has been the subject of a number of other reports. Argus upgraded shares of Teva Pharmaceutical Industries from a hold rating to a buy rating and set […]

Stock analysts at StockNews.com initiated coverage on shares of trivago (NASDAQ:TRVG – Get Free Report) in a research note issued to investors on Wednesday. The firm set a “buy” rating on the technology company’s stock. Separately, Susquehanna reduced their price target on trivago from $2.50 to $2.25 and set a “neutral” rating for the company […]

TD Securities set a C$46.00 target price on Spin Master (TSE:TOY – Free Report) in a research report released on Tuesday morning, BayStreet.CA reports. The firm currently has a buy rating on the stock. Separately, Royal Bank of Canada lifted their price objective on Spin Master from C$46.00 to C$47.00 in a research report on […]

Cogent Biosciences (NASDAQ:COGT – Free Report) had its price target boosted by Citigroup from $13.00 to $15.00 in a report issued on Tuesday, Benzinga reports. Citigroup currently has a buy rating on the technology company’s stock. A number of other research analysts also recently issued reports on the company. JPMorgan Chase & Co. decreased their […]